Wendy Perrow is the CEO of AsclepiX Therapeutics and is responsible for managing the Company's business, clinical, financial, licensing, and corporate development efforts. Ms. Perrow previously served as CEO of Alba Therapeutics.

Under her leadership, Alba Therapeutics completed a licensing agreement with Innovate Biopharmaceuticals, Inc. on February 29, 2016. The company conducted seven clinical trials in patients with Celiac Disease, completed the largest Phase IIb clinical trial in patients with celiac disease and validated the 1 st Celiac Disease Patient Reported Outcome (CeD PRO) with the lead compound Larazotide Acetate.

Prior to joining AscepiX, Ms. Perrow held senior executive positions with private and public pharmaceutical companies. From 2004 to 2007, she was Vice President of Marketing for Sigma-Tau Pharmaceuticals, Inc., a company focused on creating novel therapies for the unmet needs of patients with Rare and Orphan Diseases. From 1989 to 2003, Ms. Perrow was at Merck and Co., Inc. in Global markets including Europe, Asia, and Latin America and U.S. At Merck, she held positions in marketing, marketing promotion, international business research analysis, training, and sales. A skilled marketer and business leader, she has led U.S. and Global launches/initiatives for Zocor®, Vasotec®, Varivax®, Cozaar® and Hyzaar®. Ms. Perrow began her career in a division of Johnson & Johnson.

Wendy received her MBA in International finance and marketing from The Fuqua School of Business at Duke University and received her bachelor’s degree from Eastern Illinois University. She is a member of the Duke Fuqua School of Business Alumni Board, Maryland Life Sciences Advisory Board, Maryland TEDCO Review Board, Healthcare Business Women's Association, and Women in Bio.

You can read more about the event here

RSVP here. RSVPs are required.